Neuland Laboratories Ltd

Neuland Laboratories Ltd

₹ 6,187 -2.23%
28 May - close price
About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Key Points

Business Segments
1. Prime APIs
This segment comprises ~15 mature large volume APIs in a highly competitive market. The key molecules in this primary revenue generating segment are Levetiracetam and Mirtazapine. [1]

  • Market Cap 7,938 Cr.
  • Current Price 6,187
  • High / Low 7,794 / 2,615
  • Stock P/E 26.5
  • Book Value 995
  • Dividend Yield 0.16 %
  • ROCE 33.3 %
  • ROE 26.5 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 79.2% CAGR over last 5 years

Cons

  • Promoter holding is low: 32.7%
  • Promoter holding has decreased over last 3 years: -3.48%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
245 201 258 236 256 221 294 269 407 363 418 393 385
219 175 215 204 217 193 225 215 287 266 280 272 278
Operating Profit 25 26 43 32 39 28 69 54 120 97 137 121 107
OPM % 10% 13% 17% 14% 15% 13% 24% 20% 29% 27% 33% 31% 28%
15 2 0 2 1 1 0 1 8 2 3 2 5
Interest 5 4 4 3 3 3 3 3 4 2 4 4 4
Depreciation 11 12 12 13 12 13 13 13 13 14 15 15 16
Profit before tax 24 12 28 18 24 13 53 39 110 84 121 104 92
Tax % 29% 28% 26% 29% 9% 26% 28% 22% 23% 25% 27% 22% 27%
17 9 20 13 22 10 38 30 85 62 89 81 68
EPS in Rs 13.43 6.74 15.85 10.09 17.01 7.67 29.88 23.73 65.87 48.50 69.42 62.90 52.70
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
461 466 469 510 579 527 667 763 937 951 1,191 1,559
402 395 402 430 473 477 609 661 790 807 919 1,097
Operating Profit 58 70 67 80 106 50 58 101 147 144 272 462
OPM % 13% 15% 14% 16% 18% 10% 9% 13% 16% 15% 23% 30%
3 3 0 2 1 4 3 4 16 0 9 13
Interest 31 25 27 24 21 19 16 22 18 13 13 14
Depreciation 15 15 15 16 19 22 26 31 40 49 53 60
Profit before tax 16 34 24 41 67 14 20 52 105 82 215 401
Tax % 12% 22% 36% 36% 30% 13% 19% 70% 23% 22% 24% 25%
14 27 16 26 46 12 16 16 80 64 163 300
EPS in Rs 15.33 29.97 17.76 29.73 52.20 13.29 12.58 12.38 62.58 49.52 127.14 233.52
Dividend Payout % 7% 9% 9% 7% 0% 0% 0% 16% 8% 10% 8% 6%
Compounded Sales Growth
10 Years: 13%
5 Years: 19%
3 Years: 18%
TTM: 31%
Compounded Profit Growth
10 Years: 27%
5 Years: 79%
3 Years: 62%
TTM: 83%
Stock Price CAGR
10 Years: 37%
5 Years: 59%
3 Years: 41%
1 Year: 136%
Return on Equity
10 Years: 12%
5 Years: 14%
3 Years: 19%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 8 8 9 9 9 9 13 13 13 13 13 13
Reserves 91 115 151 175 534 546 683 693 769 823 975 1,264
210 190 188 182 192 319 231 264 182 241 128 95
116 171 164 157 150 197 203 260 359 306 463 459
Total Liabilities 425 483 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831
136 131 123 139 466 475 541 653 716 767 758 824
CWIP 36 35 41 40 20 126 104 24 17 20 41 46
Investments 8 8 8 8 8 8 8 8 7 4 1 1
246 310 339 337 392 462 476 545 583 590 781 960
Total Assets 425 483 511 523 885 1,071 1,130 1,230 1,324 1,382 1,579 1,831

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
26 49 13 45 39 12 70 57 189 60 239 260
-7 -10 -14 -20 -42 -116 -77 -49 -84 -96 -62 -150
-20 -39 1 -24 -0 105 12 -5 -114 38 -136 -69
Net Cash Flow -1 0 0 1 -3 0 4 2 -9 3 41 41

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 78 93 100 85 114 134 90 91 85 90 111 87
Inventory Days 124 138 170 182 188 268 191 209 205 227 211 222
Days Payable 110 138 167 124 123 198 123 114 130 105 135 126
Cash Conversion Cycle 92 93 103 144 179 205 158 186 160 212 187 184
Working Capital Days 75 87 123 113 137 174 124 128 92 122 94 96
ROCE % 15% 19% 16% 18% 16% 4% 4% 8% 11% 10% 21%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
36.22% 36.22% 36.22% 36.22% 36.22% 36.22% 36.14% 36.14% 36.03% 35.97% 32.80% 32.74%
15.51% 16.03% 17.21% 17.21% 17.39% 17.68% 17.70% 18.14% 20.19% 21.57% 22.69% 24.43%
4.42% 5.65% 6.17% 6.38% 6.45% 6.57% 6.54% 7.10% 6.76% 6.99% 6.02% 6.54%
0.00% 0.00% 0.00% 0.00% 0.00% 0.44% 0.46% 0.40% 0.40% 0.40% 0.40% 0.40%
43.85% 42.10% 40.40% 40.19% 39.94% 39.07% 39.15% 38.22% 36.62% 35.08% 38.10% 35.88%
No. of Shareholders 34,97834,33232,42632,25731,97630,60029,66926,94825,22326,82427,72328,616

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls